Proactive Investors - Run By Investors For Investors

OptiBiotix Health signs manufacturing and supply agreement with US Pharma Lab

Per Rehne, chief commercial director of OptiBiotix Health plc (LON:OPTI), discusses with Proactive's Andrew Scott a manufacturing and supply agreement they've signed with a US-based probiotic maker for its LPLDL probiotic strain.

Rehne says under the agreement, US Pharma Lab Inc (USPL) will be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain.

 
Meet Cornish Lithium, Salt Lake Potash Ltd and Concepta at our event, London , 05 June 2019. Register here »
View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use